Editorial Board member, Eleni Andreopoulou, spoke to us at the 2019 ASCO annual meeting about the advances made in immunotherapy for the treatment of breast cancer.
In Part 1 Eleni discusses the rationale and evidence that supports the use of immune checkpoint inhibitors.
1. What is the rationale for the use of immune checkpoint inhibitors in breast cancer, which has historically been viewed as not immunogenic? (0:04)
2. What clinical evidence supports the use of immune checkpoint inhibitors in early stage and metastatic breast cancer? (1:28)
Speaker disclosure: Eleni Andreopoulou has nothing to disclosure in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Breast Cancer
Javier Cortés, ESMO 2021: Results of the Randomized Phase III DESTINY-Breast03 Study
touchONCOLOGY joins Dr Javier Cortés at ESMO 2021 to discuss the much-anticipated results of the randomized phase III DESTINY-Breast03 study. Questions 1. Why are antibody-drug conjugates needed in the treatment of HER2+ metastatic breast cancer? (00:17-01:17) 2. What were the objectives of the phase III DESTINY-Breast03 study? (01:17-01:55) 3. Could you tell us a little […]
Sara Tolaney, ASCO 2021: Abemaciclib in HR+, HER2+ high-risk early breast cancer
touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer. The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer […]
Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!